Teva (TEVA) provides an update on a Phase III trial for Milprosa: 1) further evidence that the...

|About: Teva Pharmaceutical Industr... (TEVA)|By:, SA News Editor

Teva (TEVA) provides an update on a Phase III trial for Milprosa: 1) further evidence that the ring "is comparable to progesterone gel in efficacy"; 2) at eight weeks, multiple pregnancy rates were higher for those treated with Milprosa compared to gel; 3) multiple live birth rates were higher with Milprosa. (Previously: progesterone hormone supplement effective for women undergoing IVF treatment)

Subscribe for full text news in your inbox